Disc Medicine Inc(IRON) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -6.58 | Insider Own | 26.67% | Shs Outstand | 38.4M | Perf Week | 8.5% |
| Market Cap | 3.59B | Forward P/E | - | EPS next Y | -5.03% | Insider Trans | -2.65% | Shs Float | 28.1M | Perf Month | 27.09% |
| Enterprise Value | 2.93B | PEG | - | EPS next Q | -1.63 | Inst Own | 97.43% | Short Float | 26.49% | Perf Quarter | 5.94% |
| Income | -0.25B | P/S | - | EPS this Y | -4.96% | Inst Trans | 3.48% | Short Ratio | 9.29 | Perf Half Y | 20.82% |
| Sales | 0.00B | P/B | 4.81 | EPS next 5Y | 7.47% | ROA | -35.12% | Short Interest | 7.46M | Perf YTD | 1.8% |
| Book/sh | 16.8 | P/C | 5 | EPS past 3/5Y | 48.9% 25.96% | ROE | -39.08% | 52W High | -18.75% ($99.50) | Perf Year | -5.73% |
| Cash/sh | 16.17 | P/FCF | - | Sales past 3/5Y | - | ROIC | -34.89% | 52W Low | 102.1% ($40.00) | Perf 3Y | 78.81% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -47% | Gross Margin | - | Volatility(W/M) | 4.91% 5.51% | Perf 5Y | 112.74% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 4.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 24.14 | EPS Q/Q | 2.44% | Profit Margin | - | RSI (14) | 64.8 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 24.14 | Sales Q/Q | - | SMA20 | 16.85% ($69.18) | Beta | 0.99 | Target Price | $125.75 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/7/30 | SMA50 | 13.28% ($71.36) | Rel Volume | 0.85 | Prev Close | $82.84 |
| Employees | 155 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | 10.07% - | SMA200 | 14.37% ($70.68) | Avg Volume(3M) | 0.80M | Price | $80.84 |
| IPO | 2020/8/12 | Option/Short | Yes/Yes | Trades | 7526 | Volume | 685,006 | Change | -2.41% |
🧬 This is a clinical-stage biotech company developing therapeutics for blood disorders. The company focuses on iron metabolism and blood disease treatments and is gaining attention for its clinical progress. It is a biotech firm specializing in therapeutics for blood disorders.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
Traded about as much as usual. That is 85% of its average volume.
IRON has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -5.0% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +112.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
SBIO ALPS Medical Breakthroughs ETF 0.02% 
FMED Fidelity Disruptive Medicine ETF 0.01% 
PTH Invesco Dorsey Wright Healthcare Momentum ETF <0.01% 
BBC Virtus Biotech Clinical Trials ETF <0.01% 
XBI State Street SPDR S&P Biotech ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
USCL iShares Climate Conscious & Transition MSCI USA ETF 2.8B 
KLMT Invesco MSCI Global Climate 500 ETF 1.6B 
PWRD TCW Transform Systems ETF 1.5B 
CRBN iShares Low Carbon Optimized MSCI ACWI ETF 1.2B 
LCTU iShares U.S. Carbon Transition Readiness Aware Active ETF 1.2B It ranks #65 of 597 in the industry
Based on market cap of $4B.
FAQ
What kind of company is IRON?
IRON belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IRON?
The market cap of IRON is approximately $3.6B, ranking 1,621 within its sector.
What is the 52-week high and low for IRON?
IRON has recorded a 52-week high of $99.50 and a low of $40.00.
